Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ergocalciferol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | TST | Q16762 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | PGR | P06401 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ergocalciferol SCHEMBL13693869 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL13526523 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL12464764 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL24855744 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL14404820 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL24565106 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL19386228 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL3422 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL20510995 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL2390787 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 883 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260063626-A1 | COMPARTMENTAL ANALYSIS OF EXTRACORPOREAL LIVER PERFUSION SYSTEMS | HEPQUANT LLC (US) | 2026-03-05 | — | — | US | claimed |
| US-20230381195-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI) AND RELATED DISORDERS | MEHRA AKHIL (US) | 2023-11-30 | — | — | US | claimed |
| EP-3837359-A1 | METHODS AND COMPOSITIONS FOR TREATING MITOCHONDRIAL DISEASE OR DISORDERS AND HETEROPLASMY | Imel Biotherapeutics, Inc. (US) | 2021-06-23 | — | — | EP | claimed |
| US-20210106592-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI) AND RELATED DISORDERS | MEHRA AKHIL (US) | 2021-04-15 | — | — | US | claimed |
| US-20200054682-A1 | METHODS AND COMPOSITIONS FOR TREATING MITOCHONDRIAL DISEASE OR DISORDERS AND HETEROPLASMY | IMEL BIOTHERAPEUTICS INC (US) | 2020-02-20 | — | — | US | claimed |
| WO-2020036973-A1 | METHODS AND COMPOSITIONS FOR TREATING MITOCHONDRIAL DISEASE OR DISORDERS AND HETEROPLASMY | Imel Biotherapeutics, Inc. (US) | 2020-02-20 | — | — | WO | claimed |
| US-20180000685-A1 | NEUROLOGIC THERAPY DEVICES, SYSTEMS, AND METHODS | NeuroRhythmics, Inc. | 2018-01-04 | — | — | US | claimed |
| WO-2018005757-A1 | NEUROLOGIC THERAPY DEVICES, SYSTEMS, AND METHODS | NeuroRhythmics, Inc. (US) | 2018-01-04 | — | — | WO | claimed |
| EP-2048852-B1 | Service aggregation system and method | FIFTHPLAY NV (BE) | 2016-01-27 | — | — | EP | claimed |
| WO-2013119326-A1 | NEUROPSYCHIATRIC TEST REPORTS | GENOMIND, LLC (US) | 2013-08-15 | — | — | WO | claimed |
| CN-101090721-A | Selective serotonin receptor inverse agonists as therapeutics for disease | ACADIA PHARM INC (US) | 2007-12-19 | — | — | CN | claimed |
| EP-1814979-A2 | TRANSPLANTATION OF HUMAN NEURAL CELLS FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS | Neuralstem, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| EP-1750705-A1 | SELECTIVE SEROTONIN RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR DISEASE | Acadia Pharmaceuticals Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2006055685-A2 | TRANSPLANTATION OF HUMAN NEURAL CELLS FOR TREATMENT OF NEURODEGENERATIVE CONDITIONS | NEURALSTEM, INC. (US) | 2006-05-26 | — | — | WO | claimed |
| WO-2005112927-A1 | SELECTIVE SEROTONIN RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR DISEASE | ACADIA PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050261278-A1 | Selective serotonin receptor inverse agonists as therapeutics for disease | ACADIA PHARMACEUTICALS INC. | 2005-11-24 | — | — | US | claimed |
| US-20040067907-A1 | Process for delivery of polynucleotides to the prostate | ROCHE MADISON INC. | 2004-04-08 | — | — | US | claimed |
| US-6250306-B1 | Assessment of ischemic wound healing therapeutics | ETHICON, INC. | 2001-06-26 | — | — | US | claimed |
| US-5858004-A | Head projections on shielded butterfly needle assemblies | SHIELDS JACK W (US) | 1999-01-12 | — | — | US | claimed |
| US-4649939-A | Mid-hind foot stabilizer | NIKE, INC. | 1987-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054682-A1 | METHODS AND COMPOSITIONS FOR TREATING MITOCHONDRIAL DISEASE OR DISORDERS AND HETEROPLASMY | MT-CO2, UQCRC2, TFAM | VDR 4542/4885ALDH1A1 2611/4885ALOX15 3237/4885 |
| US-20050261278-A1 | Selective serotonin receptor inverse agonists as therapeutics for disease | HTR7, HTR6, HTR3B | VDR 310/4885ALDH1A1 3248/4885ALOX15 1875/4885 |
| US-20260063626-A1 | COMPARTMENTAL ANALYSIS OF EXTRACORPOREAL LIVER PERFUSION SYSTEMS | SLC10A1, ABCB11, SLC10A2 | VDR 1007/4885ALDH1A1 4224/4885ALOX15 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.